Developer docs
API playgroundTry for free, no card

Search company profiles

Compass Therapeutics

Full company profile

uuid0000doy

Namestring
Compass Therapeutics
Legal namestring
Compass Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing next-generation antibody therapeutics that target the immune synapse to overcome resistance to anti-angiogenic and checkpoint inhibitor therapies. The company operates a platform-plus-pipeline model: a proprietary antibody discovery engine combining a common light chain-focused antibody discovery platform, a mammalian human display platform for antibody tuning, and the StitchMabs™ high-throughput multispecific screening platform that covalently links monoclonal antibodies into customized bispecific formats. This platform has drugged more than 40 immune targets and generated thousands of epitopically and functionally varied candidates. The pipeline is led by tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody in Phase 2/3 (COMPANION-002) for second-line biliary tract cancer, which met its primary ORR endpoint (17.1% vs 5.3%, p=0.031) and PFS secondary endpoint (HR=0.44, p<0.0001) but missed overall survival due to 54% patient crossover. Additional clinical assets include CTX-471 (CD137 agonist), CTX-8371 (PD-1 x PD-L1 bispecific, 33% ORR in checkpoint-fail patients), and CTX-10726 (PD-1 x VEGF-A, IND cleared Q1 2026).

The company's revenue model is entirely pre-commercial. Compass has no approved products, generates no product revenue, and is funded through equity financings — most recently a $129 million public offering in 2025 — with $195 million in cash and marketable securities as of Q1 2026 providing runway into 2028. Net losses were $66.5 million in 2025 and $18.3 million in Q1 2026. Future revenue is expected to come from direct commercialization of proprietary oncology therapeutics (initially tovecimig) supported by the appointment of a Chief Commercial Officer in January 2026, supplemented by potential platform licensing and discovery collaborations. Compass is publicly listed on NASDAQ under ticker CMPX, headquartered in Boston, and was co-founded in 2014 by Thomas J. Schuetz, MD, PhD following his tenure as a venture partner at OrbiMed.

The company's customer-facing motion is currently clinical-trial-driven: investigational therapies are delivered exclusively through 25+ U.S. academic medical centers and community oncology sites (Mayo Clinic, MD Anderson, Mass General, UCSF, Stanford, Johns Hopkins) participating in multi-center studies. Following the planned BLA submission for tovecimig later in 2026, the company intends to transition to an enterprise field sales model for commercial launch in biliary tract cancer and other oncology indications.

Short descriptiontext

Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing next-generation bispecific antibody therapeutics to overcome resistance to anti-angiogenic and checkpoint inhibitor therapies. Its pipeline is led by tovecimig (CTX-009), a DLL4 x VEGF-A bispecific in Phase 2/3 for biliary tract cancer, supported by a proprietary StitchMabs™ antibody discovery platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology antibody therapeutics, bispecific antibody development, immuno-oncology drug discovery, clinical-stage biopharmaceuticals, antibody discovery platforms
Industry3 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-revenue clinical-stage operations
TypeLicensing Royalties
Description

Clinical-stage oncology biopharmaceutical company with no commercial product sales. Operations are funded through equity financings (e.g., $80M PIPE in 2022, $129M public offering, $400M mixed shelf offering filed December 2025). Net loss of $66.5 million in 2025 and $18.3 million in Q1 2026; cash and marketable securities of $195 million expected to fund operations into 2028 ahead of a planned BLA submission for tovecimig.

stocktitan.net
2Future commercial drug sales (planned)
TypeOne Time License
Description

Future revenue model centers on direct commercialization of proprietary oncology antibody therapeutics, beginning with tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody targeting biliary tract cancer, supported by the appointment of a Chief Commercial Officer in January 2026. Company is also actively seeking strategic partners and discovery collaborations around StitchMabs™ and common light chain platforms.

compasstherapeutics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1No commercial product pricing is publicly available; clinical-stage oncology therapeutics are not yet marketed.
ModelOtherBilling cadencePay-as-you-go
Notes

Clinical-stage biopharmaceutical company with no approved products; pricing will be determined at potential commercial launch.

compasstherapeutics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Compass Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of proprietary antibody therapeutic candidates for oncology, anchored by the bispecific antibody tovecimig (CTX-009) targeting DLL4 and VEGF-A in biliary tract cancer, with additional bispecific (CTX-8371, CTX-10726) and agonistic monoclonal (CTX-471) candidates. The pipeline is generated and supported by two proprietary discovery platforms — the StitchMabs™ high-throughput multispecific antibody screening platform and a common light chain antibody discovery platform — which together have drugged more than 40 immune targets and produced thousands of monoclonal and multispecific candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Progression-free survival of 4.7 months vs 2.6 months (HR=0.44, p<0.0001), representing a 56% reduction in risk of progression for tovecimig+paclitaxel vs paclitaxel alone in second-line biliary tract cancer (COMPANION-002 Phase 2/3)
+5 more records
Product overview1 text field

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing a platform-plus-pipeline architecture. The foundation is a proprietary antibody discovery engine comprising the Common Light Chain Antibody Discovery Platform and the StitchMabs™ multispecific screening platform, which together allow the company to empirically generate and screen thousands of monoclonal and multispecific antibody candidates against more than 40 immune targets. On top of this platform sits a focused pipeline of antibody-based therapeutic candidates spanning multiple modalities and stages: the lead clinical asset Tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody in Phase 2/3 for biliary tract cancer with a planned BLA submission; the clinical assets CTX-471 (CD137 agonist) and CTX-8371 (PD-1 x PD-L1 bispecific); the newly IND-cleared CTX-10726 (PD-1 x VEGF-A bispecific) entering Phase 1; and an ongoing discovery effort evaluating additional bispecifics and trispecifics that combine angiogenesis and immune-modulating targets.

Product and service6 records
1Tovecimig (CTX-009)
CategoryClinical-stage bispecific antibody therapeutic candidate
Description

Bispecific antibody simultaneously targeting DLL4 and VEGF-A, in development for second-line biliary tract cancer (with paclitaxel), third- and fourth-line metastatic colorectal cancer (monotherapy), and other DLL4-positive solid tumors. Phase 2/3 COMPANION-002 met primary ORR (17.1% vs 5.3%, p=0.031) and PFS (4.7 vs 2.6 months, HR=0.44, p<0.0001) endpoints; received FDA Orphan Drug Designation in April 2026.

2CTX-471
CategoryClinical-stage agonistic monoclonal antibody therapeutic candidate
Description

Agonistic monoclonal antibody directed against the co-stimulatory molecule CD137 (4-1BB) that delivers a potent costimulatory signal to activated T cells and other effector cells. Designed for patients with solid tumors and hematologic malignancies refractory to checkpoint inhibitor therapy; new NCAM-positive tumor basket study planned to initiate in Q1 2026.

3CTX-8371
CategoryClinical-stage bispecific antibody therapeutic candidate
Description

Bispecific antibody simultaneously targeting PD-1 and PD-L1. Phase 1 expansion cohorts are being enrolled in NSCLC, TNBC, and Hodgkin lymphoma based on dose-escalation responses, with 33% ORR at top dose levels in patients who previously failed checkpoint inhibitor therapy.

4CTX-10726
CategoryClinical-stage bispecific antibody therapeutic candidate
Description

Tetravalent bispecific antibody simultaneously targeting PD-1 and VEGF-A. Designed so that modulation of the tumor microenvironment via VEGF targeting improves the efficacy of PD-1 blockade. FDA-cleared IND with Phase 1 enrollment initiated in Q1 2026.

5StitchMabs™ Multispecific Antibody Screening Platform
CategoryProprietary antibody discovery platform (offered for licensing and discovery collaborations)
Description

Proprietary, high-throughput multispecific antibody screening platform that covalently links two or more monoclonal antibodies, antibody fragments, or other biologics into customized bi- and multispecific formats in minutes using peptide tags for irreversible peptide bond formation, enabling large matrix screening experiments to identify novel and potentially unexpected synergistic combinations.

6Common Light Chain Antibody Discovery Platform
CategoryProprietary antibody discovery platform (offered for licensing and discovery collaborations)
Description

Proprietary in vitro and in vivo platforms for the generation of highly diverse antibody panels based on a single light chain sequence. To date, more than 40 immune targets have been drugged, delivering thousands of epitopically and functionally varied leads that can be screened for combination synergy as cocktails or bispecifics, with bispecific candidates exhibiting monoclonal-like expression, stability, and pharmacokinetics.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1TRIGR Therapeutics
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-05-13
Description

Compass Therapeutics acquired TRIGR Therapeutics, Inc. through a stock-for-stock transaction announced on May 13, 2021, with the deal expected to close in Q2 2021. The acquisition delivered CTX-009 (later renamed tovecimig), a promising bispecific antibody targeting DLL4 and VEGF-A, which has shown positive preliminary clinical results in solid tumors and became Compass's lead clinical-stage asset.

biospace.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Astellas Pharma acquired Audentes Therapeutics, a company co-founded by Compass CEO Thomas J. Schuetz, in a transaction referenced in his biography. The relationship reflects historical venture connections rather than an active product partnership with Compass.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology company developing bispecific antibodies including PD-1 x PD-L1 candidates (lorigerlimab) and other immuno-oncology bispecifics; directly competes with CTX-8371 in the checkpoint bispecific space.

TypeBroad incumbent
Description

Large biopharmaceutical company with approved bispecific antibodies (linvoseltamab, odronextamab) and a VelociSuite antibody discovery platform; comparable bispecific modality and platform technology though operating at much larger scale with multiple marketed products.

TypeDirect peer
Description

Clinical-stage biotech developing engineered multispecific antibodies, including bispecifics targeting oncology pathways; directly comparable platform-plus-pipeline model with proprietary antibody engineering technology.

TypeEmerging player
Description

Clinical-stage biotech with a power-driven antibody discovery and engineering platform targeting oncology; comparable platform-plus-pipeline structure though at earlier development stage.

TypeDirect peer
Description

Clinical-stage company developing T cell engager bispecifics for oncology; comparable bispecific modality and clinical-stage positioning though focused on T cell engagers rather than checkpoint/angiogenesis bispecifics.

TypeDirect peer
Description

Clinical-stage biotech with a broad bispecific antibody pipeline using proprietary XmAb technology; comparable platform-driven approach to generating differentiated multispecific oncology therapeutics.

TypeDirect peer
Description

Clinical-stage biotech developing multispecific biologics for oncology and rare diseases with proprietary single-domain antibody platform; comparable multispecific therapeutic approach and clinical-stage status.

8Atreca
TypeEmerging player
Description

Clinical-stage antibody discovery company using immune repertoire analysis to identify novel antibody therapeutics; comparable antibody discovery platform approach though with different technological foundation.

TypeEmerging player
Description

Emerging biotech developing conditionally active T cell engager bispecifics; comparable multispecific antibody modality with narrower therapeutic focus on T cell engagement.

TypeBroad incumbent
Description

Large biopharmaceutical company with extensive bispecific antibody pipeline (e.g., datopotamab, volrustomig) and a history of antibody innovation through MedImmune; comparable bispecific therapeutic approach at much larger scale with multiple approved oncology antibodies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors33 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Compass Therapeutics

Clinical-stage Oncology Biopharmaceuticalscompasstherapeutics.com

Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing next-generation bispecific antibody therapeutics to overcome resistance to anti-angiogenic and checkpoint inhibitor therapies. Its pipeline is led by tovecimig (CTX-009), a DLL4 x VEGF-A bispecific in Phase 2/3 for biliary tract cancer, supported by a proprietary StitchMabs™ antibody discovery platform.

What Compass Therapeutics does

Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing next-generation antibody therapeutics that target the immune synapse to overcome resistance to anti-angiogenic and checkpoint inhibitor therapies. The company operates a platform-plus-pipeline model: a proprietary antibody discovery engine combining a common light chain-focused antibody discovery platform, a mammalian human display platform for antibody tuning, and the StitchMabs™ high-throughput multispecific screening platform that covalently links monoclonal antibodies into customized bispecific formats. This platform has drugged more than 40 immune targets and generated thousands of epitopically and functionally varied candidates. The pipeline is led by tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody in Phase 2/3 (COMPANION-002) for second-line biliary tract cancer, which met its primary ORR endpoint (17.1% vs 5.3%, p=0.031) and PFS secondary endpoint (HR=0.44, p<0.0001) but missed overall survival due to 54% patient crossover. Additional clinical assets include CTX-471 (CD137 agonist), CTX-8371 (PD-1 x PD-L1 bispecific, 33% ORR in checkpoint-fail patients), and CTX-10726 (PD-1 x VEGF-A, IND cleared Q1 2026).

The company's revenue model is entirely pre-commercial. Compass has no approved products, generates no product revenue, and is funded through equity financings — most recently a $129 million public offering in 2025 — with $195 million in cash and marketable securities as of Q1 2026 providing runway into 2028. Net losses were $66.5 million in 2025 and $18.3 million in Q1 2026. Future revenue is expected to come from direct commercialization of proprietary oncology therapeutics (initially tovecimig) supported by the appointment of a Chief Commercial Officer in January 2026, supplemented by potential platform licensing and discovery collaborations. Compass is publicly listed on NASDAQ under ticker CMPX, headquartered in Boston, and was co-founded in 2014 by Thomas J. Schuetz, MD, PhD following his tenure as a venture partner at OrbiMed.

The company's customer-facing motion is currently clinical-trial-driven: investigational therapies are delivered exclusively through 25+ U.S. academic medical centers and community oncology sites (Mayo Clinic, MD Anderson, Mass General, UCSF, Stanford, Johns Hopkins) participating in multi-center studies. Following the planned BLA submission for tovecimig later in 2026, the company intends to transition to an enterprise field sales model for commercial launch in biliary tract cancer and other oncology indications.

Compass Therapeutics firmographics

Firmographics
Name
Compass Therapeutics
Legal name
Compass Therapeutics, Inc.
Website
https://compasstherapeutics.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing next-generation bispecific antibody therapeutics to overcome resistance to anti-angiogenic and checkpoint inhibitor therapies. Its pipeline is led by tovecimig (CTX-009), a DLL4 x VEGF-A bispecific in Phase 2/3 for biliary tract cancer, supported by a proprietary StitchMabs™ antibody discovery platform.
Ownership category
akta.pro rank

Compass Therapeutics industry classification

Industry
Product category
Clinical-stage Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Oncology antibody therapeutics
  • Bispecific antibody development
  • Immuno-oncology drug discovery
  • Clinical-stage biopharmaceuticals
  • Antibody discovery platforms

Where Compass Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Compass Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pre-revenue clinical-stage operations: Clinical-stage oncology biopharmaceutical company with no commercial product sales. Operations are funded through equity financings (e.g., $80M PIPE in 2022, $129M public offering, $400M mixed shelf offering filed December 2025). Net loss of $66.5 million in 2025 and $18.3 million in Q1 2026; cash and marketable securities of $195 million expected to fund operations into 2028 ahead of a planned BLA submission for tovecimig.
  2. Future commercial drug sales (planned): Future revenue model centers on direct commercialization of proprietary oncology antibody therapeutics, beginning with tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody targeting biliary tract cancer, supported by the appointment of a Chief Commercial Officer in January 2026. Company is also actively seeking strategic partners and discovery collaborations around StitchMabs™ and common light chain platforms.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNo commercial product pricing is publicly available; clinical-stage oncology therapeutics are not yet marketed.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels7 records

Compass Therapeutics product offering

Product offering

Core offering

Compass Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of proprietary antibody therapeutic candidates for oncology, anchored by the bispecific antibody tovecimig (CTX-009) targeting DLL4 and VEGF-A in biliary tract cancer, with additional bispecific (CTX-8371, CTX-10726) and agonistic monoclonal (CTX-471) candidates. The pipeline is generated and supported by two proprietary discovery platforms — the StitchMabs™ high-throughput multispecific antibody screening platform and a common light chain antibody discovery platform — which together have drugged more than 40 immune targets and produced thousands of monoclonal and multispecific candidates.

Product overview

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing a platform-plus-pipeline architecture. The foundation is a proprietary antibody discovery engine comprising the Common Light Chain Antibody Discovery Platform and the StitchMabs™ multispecific screening platform, which together allow the company to empirically generate and screen thousands of monoclonal and multispecific antibody candidates against more than 40 immune targets. On top of this platform sits a focused pipeline of antibody-based therapeutic candidates spanning multiple modalities and stages: the lead clinical asset Tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody in Phase 2/3 for biliary tract cancer with a planned BLA submission; the clinical assets CTX-471 (CD137 agonist) and CTX-8371 (PD-1 x PD-L1 bispecific); the newly IND-cleared CTX-10726 (PD-1 x VEGF-A bispecific) entering Phase 1; and an ongoing discovery effort evaluating additional bispecifics and trispecifics that combine angiogenesis and immune-modulating targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tovecimig (CTX-009) Bispecific antibody simultaneously targeting DLL4 and VEGF-A, in development for second-line biliary tract cancer (with paclitaxel), third- and fourth-line metastatic colorectal cancer (monotherapy), and other DLL4-positive solid tumors. Phase 2/3 COMPANION-002 met primary ORR (17.1% vs 5.3%, p=0.031) and PFS (4.7 vs 2.6 months, HR=0.44, p<0.0001) endpoints; received FDA Orphan Drug Designation in April 2026.
  • CTX-471 Agonistic monoclonal antibody directed against the co-stimulatory molecule CD137 (4-1BB) that delivers a potent costimulatory signal to activated T cells and other effector cells. Designed for patients with solid tumors and hematologic malignancies refractory to checkpoint inhibitor therapy; new NCAM-positive tumor basket study planned to initiate in Q1 2026.
  • CTX-8371 Bispecific antibody simultaneously targeting PD-1 and PD-L1. Phase 1 expansion cohorts are being enrolled in NSCLC, TNBC, and Hodgkin lymphoma based on dose-escalation responses, with 33% ORR at top dose levels in patients who previously failed checkpoint inhibitor therapy.
  • CTX-10726 Tetravalent bispecific antibody simultaneously targeting PD-1 and VEGF-A. Designed so that modulation of the tumor microenvironment via VEGF targeting improves the efficacy of PD-1 blockade. FDA-cleared IND with Phase 1 enrollment initiated in Q1 2026.
  • StitchMabs™ Multispecific Antibody Screening Platform Proprietary, high-throughput multispecific antibody screening platform that covalently links two or more monoclonal antibodies, antibody fragments, or other biologics into customized bi- and multispecific formats in minutes using peptide tags for irreversible peptide bond formation, enabling large matrix screening experiments to identify novel and potentially unexpected synergistic combinations.
  • Common Light Chain Antibody Discovery Platform Proprietary in vitro and in vivo platforms for the generation of highly diverse antibody panels based on a single light chain sequence. To date, more than 40 immune targets have been drugged, delivering thousands of epitopically and functionally varied leads that can be screened for combination synergy as cocktails or bispecifics, with bispecific candidates exhibiting monoclonal-like expression, stability, and pharmacokinetics.

Quantifiable outcome

  • Progression-free survival of 4.7 months vs 2.6 months (HR=0.44, p<0.0001), representing a 56% reduction in risk of progression for tovecimig+paclitaxel vs paclitaxel alone in second-line biliary tract cancer (COMPANION-002 Phase 2/3)
  • +5 more outcomes

Companies that use Compass Therapeutics

Customer profile

Segments4 records

Ideal customer profiles3 records

Compass Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Compass Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and minor.

  • TRIGR TherapeuticsflagshipStrategic or Co-development Partner · 13 May 2021Compass Therapeutics acquired TRIGR Therapeutics, Inc. through a stock-for-stock transaction announced on May 13, 2021, with the deal expected to close in Q2 2021. The acquisition delivered CTX-009 (later renamed tovecimig), a promising bispecific antibody targeting DLL4 and VEGF-A, which has shown positive preliminary clinical results in solid tumors and became Compass's lead clinical-stage asset.
  • Astellas PharmaminorStrategic or Co-development Partner · 1 January 2014Astellas Pharma acquired Audentes Therapeutics, a company co-founded by Compass CEO Thomas J. Schuetz, in a transaction referenced in his biography. The relationship reflects historical venture connections rather than an active product partnership with Compass.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Compass Therapeutics competitors and assessment

Company assessment

Direct peers

  • MacroGenics: Clinical-stage oncology company developing bispecific antibodies including PD-1 x PD-L1 candidates (lorigerlimab) and other immuno-oncology bispecifics; directly competes with CTX-8371 in the checkpoint bispecific space.
  • Zymeworks: Clinical-stage biotech developing engineered multispecific antibodies, including bispecifics targeting oncology pathways; directly comparable platform-plus-pipeline model with proprietary antibody engineering technology.
  • Harpoon Therapeutics: Clinical-stage company developing T cell engager bispecifics for oncology; comparable bispecific modality and clinical-stage positioning though focused on T cell engagers rather than checkpoint/angiogenesis bispecifics.
  • Xencor: Clinical-stage biotech with a broad bispecific antibody pipeline using proprietary XmAb technology; comparable platform-driven approach to generating differentiated multispecific oncology therapeutics.
  • Inhibrx Biosciences: Clinical-stage biotech developing multispecific biologics for oncology and rare diseases with proprietary single-domain antibody platform; comparable multispecific therapeutic approach and clinical-stage status.

Broad incumbents

  • Regeneron: Large biopharmaceutical company with approved bispecific antibodies (linvoseltamab, odronextamab) and a VelociSuite antibody discovery platform; comparable bispecific modality and platform technology though operating at much larger scale with multiple marketed products.
  • AstraZeneca (MedImmune): Large biopharmaceutical company with extensive bispecific antibody pipeline (e.g., datopotamab, volrustomig) and a history of antibody innovation through MedImmune; comparable bispecific therapeutic approach at much larger scale with multiple approved oncology antibodies.

Emerging players

  • Adagene: Clinical-stage biotech with a power-driven antibody discovery and engineering platform targeting oncology; comparable platform-plus-pipeline structure though at earlier development stage.
  • Atreca: Clinical-stage antibody discovery company using immune repertoire analysis to identify novel antibody therapeutics; comparable antibody discovery platform approach though with different technological foundation.
  • Maverick Therapeutics: Emerging biotech developing conditionally active T cell engager bispecifics; comparable multispecific antibody modality with narrower therapeutic focus on T cell engagement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compass Therapeutics social profiles

Digital presence

Compass Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Compass Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Compass Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Compass Therapeutics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors33 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Compass Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Compass Therapeutics

What does Compass Therapeutics do?

Compass Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of proprietary antibody therapeutic candidates for oncology, anchored by the bispecific antibody tovecimig (CTX-009) targeting DLL4 and VEGF-A in biliary tract cancer, with additional bispecific (CTX-8371, CTX-10726) and agonistic monoclonal (CTX-471) candidates. The pipeline is generated and supported by two proprietary discovery platforms — the StitchMabs™ high-throughput multispecific antibody screening platform and a common light chain antibody discovery platform — which together have drugged more than 40 immune targets and produced thousands of monoclonal and multispecific candidates.

Is Compass Therapeutics a public or private company?

Compass Therapeutics is a public company. It is classified as public and is currently operating.

When was Compass Therapeutics founded?

Compass Therapeutics was founded in 2014. It employs 51 to 100 people.

Where is Compass Therapeutics based?

Compass Therapeutics is headquartered in Boston, United States, in the North America region.

How does Compass Therapeutics make money?

Two revenue lines are on record. Pre-revenue clinical-stage operations are the primary driver. The others are future commercial drug sales (planned).

Who are Compass Therapeutics's main competitors?

Direct peers on record are MacroGenics, Zymeworks, Harpoon Therapeutics, Xencor and Inhibrx Biosciences. Broad incumbents are Regeneron and AstraZeneca (MedImmune). Emerging players are Adagene, Atreca and Maverick Therapeutics.

Does Compass Therapeutics have an API?

No public API is recorded for Compass Therapeutics.

What industry is Compass Therapeutics in?

Compass Therapeutics's product category is Clinical-stage Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewCompass Therapeutics, Inc. Stock 12‑Month Price Target Cut to $5.26, Implies 580% UpsideAnalysts' average price target for Compass Therapeutics fell from $5.33 to $5.26, implying about 580% upside from the Nov. 13 closing price. The consensus remains a Buy across 15 analysts, with 12 Buys, 3 Holds, and 0 Sells.Investing.comCompass Therapeutics at Stifel 2026 Healthcare Conference 2026: FDA path in focusCompass Therapeutics outlined its oncology strategy at the Stifel 2026 Healthcare Conference, focusing on tovecimig for biliary tract cancer. The company reported a post-hoc COMPANION-002 analysis with an overall survival hazard ratio of 0.85 and a progression-free survival hazard ratio of 0.44, and plans to re-engage the FDA for an accelerated approval path. It holds $163 million in cash, sufficient to fund operations into 2028.Investing.comCompass Therapeutics presents data on CTX-10726 mechanismCompass Therapeutics presented data on CTX-10726, a PD-1 x VEGF-A bispecific antibody, at the Society for Immunotherapy of Cancer meeting. The drug cleaves PD-1 receptors from T cells when VEGF-A is present, increasing potency ten-fold in an immune-cell assay. A Phase 1 dose-escalation study is ongoing in patients with advanced solid tumors.Business & FinancialCompass Therapeutics To Participate In Upcoming November Investor EventsCompass Therapeutics will participate in two investor events in November 2026: a Guggenheim conference on November 9 and a Stifel conference on November 11. Management will be available for one-on-one meetings, and presentations will be archived on the company's Events page.Stock TitanCompass Therapeutics to Join Two November Investor EventsCompass Therapeutics will participate in the Guggenheim healthcare investor conference on November 9, 2026, and Stifel's conference on November 11, 2026. Management will be available for one-on-one meetings during both events, with presentations archived on the company's Events page.MarketBeatCompass Therapeutics, Inc. (NASDAQ:CMPX) Stock Rated "Moderate Buy" by Sell-Side BrokeragesCompass Therapeutics received a consensus 'Moderate Buy' rating from seventeen brokerages, with an average 12-month price target of $10.25. The stock opened at $0.76, and institutional investors hold 68.43% of shares. Analysts forecast a fiscal-year EPS of -$0.47.Markets DailyCompass Therapeutics (CMPX) Projected to Release Quarterly Earnings on WednesdayCompass Therapeutics is set to release Q3 2026 earnings on Wednesday, November 4th, with analysts expecting a loss of $0.12 per share and revenue of $0.23 million. The company's stock opened at $0.75, and analysts have a consensus rating of Moderate Buy with an average target price of $10.25.MarketBeatCompass Therapeutics (CMPX) Set to Post Quarterly Earnings on WednesdayCompass Therapeutics is set to report Q3 2026 earnings on Wednesday, with analysts expecting a loss of $0.12 per share and revenue of $0.23 million. The company's stock opened at $0.75, and analysts have a consensus rating of Moderate Buy with an average price target of $10.25.The future of tradingCompass Therapeutics' Tovecimig Combination Cuts Progression or Death Risk 56% in Biliary Tract Cancer TrialCompass Therapeutics published Phase 2/3 COMPANION-002 results for tovecimig in previously treated advanced biliary tract cancer, showing improved tumor response and delayed progression versus paclitaxel alone. The combination met primary and key secondary goals, but no overall survival benefit emerged due to crossover. No new safety signals appeared, though severe adverse events and discontinuations were more frequent.TradingViewCompass Therapeutics, Inc. (CMPX) Reports Positive Phase 2/3 BTC ResultsCompass Therapeutics published Phase 2/3 data for tovecimig plus paclitaxel in previously treated advanced biliary tract cancer, meeting primary and key secondary endpoints. The treatment improved ORR to 18.0% versus 5.3% and median PFS to 4.7 versus 2.6 months, with a 56% reduction in progression or death risk. A post hoc OS analysis showed a hazard ratio of 0.85, though not statistically significant.